Categories: CancerNewsNursing

Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis

NORTHAMPTON, MA / ACCESSWIRE / June 5, 2024 / Emma was a 28-year-old nursing student when she was diagnosed with triple-negative breast cancer. She had always wanted children and, once she learned that her treatment could affect her fertility, she found herself needing to make a quick family planning decision to pursue in vitro fertilization (IVF) and freeze her eggs.

“You think that you have time to have all these things happen, and you don’t,” says Emma. “Your life is put on hold and your future’s put on hold, and who knows if you even could have kids.”

According to the National Breast Cancer Foundation, about 9% of women diagnosed with breast cancer in the United States are younger than 45 years old. While surgery and radiation rarely affect fertility, women who undergo chemotherapy can experience immediate or long-term infertility if eggs become damaged or destroyed. Other cancer treatments, such as hormone therapy, aren’t known to cause infertility, but the treatment duration could interfere with the biological clock of childbearing years.

Gilead partners with various organizations that support people living with breast cancer. One such organization, the Young Survival Coalition (YSC), recognizes the unique needs of people of childbearing age and works with patients under 40 through nearly every facet of their cancer treatment journey.

“People may tell you to focus on treating your cancer first, but it’s important that you also consider life after cancer treatment and the impact of any treatment you may choose,” says Amanda Nixon, YSC’s Director of Community Engagement and Empowerment. She says her organization always recommends that younger women diagnosed with cancer seek a consultation from a fertility preservation expert if having biological children is of interest.

Watch the video above to learn about two women’s fertility journey.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Staff

Recent Posts

WillowWood Rebrand by DD.NYC Wins Gold Anthem Award for Product and Innovation in 2024 Rebrand

MT. STERLING, Ohio, Dec. 20, 2024 /PRNewswire/ -- WillowWood, a global leader in prosthetic solutions,…

3 hours ago

Quantum Biopharma Announces Closing of Second Tranche

TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma"…

6 hours ago

Glow Lifetech Announces Completion of Final Payment under Swiss Pharma Share Exchange Agreement and Debt Settlement

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Glow Lifetech Corp. (CSE: GLOW) (OTC Pink:…

8 hours ago

Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.

Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton)…

9 hours ago

Thought Technology Ltd Celebrates 50 Years of Innovation and Excellence

Montreal-based Thought Technology Ltd wraps up its 50th year in business providing psychophysiological instrumentation to…

9 hours ago

Study Finds Telemedicine Improves Care for Children with Eye Cancer

The new research from eye care nonprofit Orbis International, supported by Heidelberg Engineering, shows how…

9 hours ago